Acquired haemophilia A after alemtuzumab therapy-Reference-Cited by-同舟云学术

Acquired haemophilia A after alemtuzumab therapy

Published:2020-07-22 Issue:6 Volume:26 Page:
ISSN:1351-8216
Container-title:Haemophilia
language:en
Short-container-title:Haemophilia

Author:

Zwan Marieke¹²^ORCID,Leebeek Frank W. G.³^ORCID,Sandberg Yorick⁴,Kruip Marieke J. H. A.³^ORCID,Hesselink Dennis A.¹²

Affiliation:

1. Department of Internal Medicine Division of Nephrology and Transplantation Erasmus MC University Medical Center Rotterdam Rotterdam The Netherlands

2. Rotterdam Transplant Group Erasmus MC University Medical Center Rotterdam Rotterdam The Netherlands

3. Department of Hematology Erasmus MC University Medical Center Rotterdam Rotterdam The Netherlands

4. Department of Internal Medicine Maasstad Hospital Rotterdam Rotterdam The Netherlands

Publisher

Wiley

Subject

Genetics(clinical),Hematology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/hae.14107

Reference11 articles.

1. Review of the Clinical Pharmacokinetics and Pharmacodynamics of Alemtuzumab and Its Use in Kidney Transplantation

2. Acquired haemophilia A after alemtuzumab treatment of multiple sclerosis

3. Acquired hemophilia A: Updated review of evidence and treatment guidance

4. Demographic and clinical data in acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2)

5. Pregnancy-associated acquired haemophilia A: results from the European Acquired Haemophilia (EACH2) registry

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Case Report: Effective management of adalimumab-induced acquired hemophilia A with the CyDRI protocol;Pathology and Oncology Research;2024-05-23

2. A Decade of Experience With Alemtuzumab Therapy for Severe or Glucocorticoid-Resistant Kidney Transplant Rejection;Transplant International;2023-11-07

3. Personalized anti-rejection therapy with alemtuzumab for kidney transplant recipients;Pharmacogenomics;2022-07

4. Clinical and Molecular Profiling to Develop a Potential Prediction Model for the Response to Alemtuzumab Therapy for Acute Kidney Transplant Rejection;Clinical Pharmacology & Therapeutics;2022-03-08

5. Alemtuzumab in multiple sclerosis: A retrospective analysis of occult hemorrhagic magnetic resonance imaging lesions and risk factors;European Journal of Neurology;2021-08-20